The European Medicines Agency (EMA) said on Monday it had concluded an inquiry into lax drug-safety reporting at Roche and sent its report to the European Commission for the next steps. The European Commission will decide whether the matter should be pursued and financial penalties should be imposed. The EMA previously said in November it had not uncovered any new safety issues connected with Roche's drugs as a result of the shortcomings in reporting adverse events. EMA launched its probe into Roche in 2012 after a routine inspection found the firm had failed to properly assess tens of thousands of cases of possible adverse drug reactions, involving 19 drugs, several of which were for cancer.
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment